Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) Other Non Operating Income (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Other Non Operating Income for 14 consecutive years, with -$77000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non Operating Income fell 492.31% to -$77000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $339000.0, a 137.21% increase, with the full-year FY2024 number at -$13000.0, up 96.48% from a year prior.
  • Other Non Operating Income was -$77000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from -$73000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $529000.0 in Q4 2024 to a low of -$460000.0 in Q1 2024.
  • A 4-year average of -$50750.0 and a median of -$71000.0 in 2024 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: soared 243.36% in 2024, then crashed 492.31% in 2025.
  • NovaBay Pharmaceuticals' Other Non Operating Income stood at -$98000.0 in 2022, then tumbled by 276.53% to -$369000.0 in 2023, then skyrocketed by 243.36% to $529000.0 in 2024, then crashed by 114.56% to -$77000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Other Non Operating Income are -$77000.0 (Q3 2025), -$73000.0 (Q2 2025), and -$40000.0 (Q1 2025).